
Sign up to save your podcasts
Or


In this episode,William G. Wierda, MD, PhD, Jeremy S. Abramson, MD, MMSc, and Brian Hill, MD, PhD, answer questions focused on personalizing therapy for patients with CLL considering patient characteristics and currently available clinical evidence.
Presenters:
William G. Wierda, MD, PhD, Program Director
Professor of Medicine
Chief, Section of CLL
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas
Jeremy S. Abramson, MD, MMSc
Associate Professor
Department of Medicine
Harvard Medical School
Director, Center for Lymphoma
Massachusetts General Hospital
Boston, Massachusetts
Brian Hill, MD, PhD
Director, Lymphoid Malignancies Program
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio
Content based on an online CME program supported by educational grants from AstraZeneca; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly.
Link to full program, including associated downloadable slidesets:
http://bit.ly/3mLjeIb
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
By Clinical Care Options4.9
99 ratings
In this episode,William G. Wierda, MD, PhD, Jeremy S. Abramson, MD, MMSc, and Brian Hill, MD, PhD, answer questions focused on personalizing therapy for patients with CLL considering patient characteristics and currently available clinical evidence.
Presenters:
William G. Wierda, MD, PhD, Program Director
Professor of Medicine
Chief, Section of CLL
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas
Jeremy S. Abramson, MD, MMSc
Associate Professor
Department of Medicine
Harvard Medical School
Director, Center for Lymphoma
Massachusetts General Hospital
Boston, Massachusetts
Brian Hill, MD, PhD
Director, Lymphoid Malignancies Program
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio
Content based on an online CME program supported by educational grants from AstraZeneca; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly.
Link to full program, including associated downloadable slidesets:
http://bit.ly/3mLjeIb
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

4,352 Listeners

318 Listeners

495 Listeners

764 Listeners

115 Listeners

57 Listeners

2,441 Listeners

3,338 Listeners

9,514 Listeners

44 Listeners

1,032 Listeners

22 Listeners

85 Listeners

57 Listeners

189 Listeners